137 related articles for article (PubMed ID: 18325101)
1. Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin.
Burkitt K; Ljungman M
Mol Cancer; 2008 Mar; 7():24. PubMed ID: 18325101
[TBL] [Abstract][Full Text] [Related]
2. Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines.
Burkitt K; Ljungman M
Cancer Lett; 2007 Aug; 253(1):131-7. PubMed ID: 17321670
[TBL] [Abstract][Full Text] [Related]
3. RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells.
Dai CH; Li J; Chen P; Jiang HG; Wu M; Chen YC
J Biomed Sci; 2015 Sep; 22(1):77. PubMed ID: 26385482
[TBL] [Abstract][Full Text] [Related]
4. Variation in cisplatinum sensitivity is not associated with Fanconi Anemia/BRCA pathway inactivation in head and neck squamous cell carcinoma cell lines.
Snyder ER; Ricker JL; Chen Z; Waes CV
Cancer Lett; 2007 Jan; 245(1-2):75-80. PubMed ID: 16466850
[TBL] [Abstract][Full Text] [Related]
5. Non-specific chemical inhibition of the Fanconi anemia pathway sensitizes cancer cells to cisplatin.
Jacquemont C; Simon JA; D'Andrea AD; Taniguchi T
Mol Cancer; 2012 Apr; 11():26. PubMed ID: 22537224
[TBL] [Abstract][Full Text] [Related]
6. Proteasome function is required for DNA damage response and fanconi anemia pathway activation.
Jacquemont C; Taniguchi T
Cancer Res; 2007 Aug; 67(15):7395-405. PubMed ID: 17671210
[TBL] [Abstract][Full Text] [Related]
7. The FA/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional Genomics.
Martens-de Kemp SR; Brink A; van der Meulen IH; de Menezes RX; Te Beest DE; Leemans CR; van Beusechem VW; Braakhuis BJ; Brakenhoff RH
Mol Cancer Ther; 2017 Mar; 16(3):540-550. PubMed ID: 27980104
[TBL] [Abstract][Full Text] [Related]
8. BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer.
Nakashima S; Kobayashi S; Nagano H; Tomokuni A; Tomimaru Y; Asaoka T; Hama N; Wada H; Kawamoto K; Marubashi S; Eguchi H; Doki Y; Mori M
Cancer Sci; 2015 May; 106(5):584-91. PubMed ID: 25736055
[TBL] [Abstract][Full Text] [Related]
9. Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments.
Kachnic LA; Li L; Fournier L; Willers H
Cancer Lett; 2010 Jun; 292(1):73-9. PubMed ID: 20034732
[TBL] [Abstract][Full Text] [Related]
10. Curcumin reverses cisplatin resistance in cisplatin-resistant lung caner cells by inhibiting FA/BRCA pathway.
Chen P; Li J; Jiang HG; Lan T; Chen YC
Tumour Biol; 2015 May; 36(5):3591-9. PubMed ID: 25542235
[TBL] [Abstract][Full Text] [Related]
11. Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.
Yarde DN; Oliveira V; Mathews L; Wang X; Villagra A; Boulware D; Shain KH; Hazlehurst LA; Alsina M; Chen DT; Beg AA; Dalton WS
Cancer Res; 2009 Dec; 69(24):9367-75. PubMed ID: 19934314
[TBL] [Abstract][Full Text] [Related]
12. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway.
Chirnomas D; Taniguchi T; de la Vega M; Vaidya AP; Vasserman M; Hartman AR; Kennedy R; Foster R; Mahoney J; Seiden MV; D'Andrea AD
Mol Cancer Ther; 2006 Apr; 5(4):952-61. PubMed ID: 16648566
[TBL] [Abstract][Full Text] [Related]
13. The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers.
D'Andrea AD
Cell Cycle; 2003; 2(4):290-2. PubMed ID: 12851475
[TBL] [Abstract][Full Text] [Related]
14. Deficiencies in the Fanconi anemia DNA damage response pathway increase sensitivity to HPV-associated head and neck cancer.
Park JW; Pitot HC; Strati K; Spardy N; Duensing S; Grompe M; Lambert PF
Cancer Res; 2010 Dec; 70(23):9959-68. PubMed ID: 20935219
[TBL] [Abstract][Full Text] [Related]
15. Activation of the Fanconi anemia/BRCA pathway and recombination repair in the cellular response to solar ultraviolet light.
Dunn J; Potter M; Rees A; Rünger TM
Cancer Res; 2006 Dec; 66(23):11140-7. PubMed ID: 17145857
[TBL] [Abstract][Full Text] [Related]
16. Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers.
Lombardi AJ; Hoskins EE; Foglesong GD; Wikenheiser-Brokamp KA; Wiesmüller L; Hanenberg H; Andreassen PR; Jacobs AJ; Olson SB; Keeble WW; Hays LE; Wells SI
Clin Cancer Res; 2015 Apr; 21(8):1962-72. PubMed ID: 25609062
[TBL] [Abstract][Full Text] [Related]
17. Arsenic exposure disrupts the normal function of the FA/BRCA repair pathway.
Peremartí J; Ramos F; Marcos R; Hernández A
Toxicol Sci; 2014 Nov; 142(1):93-104. PubMed ID: 25092648
[TBL] [Abstract][Full Text] [Related]
18. Histone H2AX and Fanconi anemia FANCD2 function in the same pathway to maintain chromosome stability.
Bogliolo M; Lyakhovich A; Callén E; Castellà M; Cappelli E; Ramírez MJ; Creus A; Marcos R; Kalb R; Neveling K; Schindler D; Surrallés J
EMBO J; 2007 Mar; 26(5):1340-51. PubMed ID: 17304220
[TBL] [Abstract][Full Text] [Related]
19. Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies.
Willers H; Taghian AG; Luo CM; Treszezamsky A; Sgroi DC; Powell SN
Mol Cancer Res; 2009 Aug; 7(8):1304-9. PubMed ID: 19671671
[TBL] [Abstract][Full Text] [Related]
20. Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA.
Ferrer M; de Winter JP; Mastenbroek DC; Curiel DT; Gerritsen WR; Giaccone G; Kruyt FA
Cancer Gene Ther; 2004 Aug; 11(8):539-46. PubMed ID: 15192709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]